There are 2867 resources available
225P - MET-enriched circulating tumor cells and cell-free DNA concentration as significant independent predictors for progression in HR-positive HER2-negative metastatic breast cancer
Presenter: Jieun Park
Session: Poster session 02
226P - Exploring the impact of first-line therapies on the metastatic behavior of luminal-like metastatic breast cancer (mBC)
Presenter: Roberta Mazzeo
Session: Poster session 02
227P - Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Presenter: Claudio Vernieri
Session: Poster session 02
228P - Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Presenter: Kenichi Watanabe
Session: Poster session 02
229P - Dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
Presenter: Ping Zhang
Session: Poster session 02
230P - Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study
Presenter: Elisa Agostinetto
Session: Poster session 02
231P - Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
Presenter: Luca Visani
Session: Poster session 02
232P - Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL
Presenter: Norbert Marschner
Session: Poster session 02
233P - Decision-making criteria for the choice of 1st line CDK4/6-inhibitor therapy for HR+/Her2- breast cancer in Germany: DECISIONext
Presenter: Dominique Finas
Session: Poster session 02
234P - CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety
Presenter: Luca Mastrantoni
Session: Poster session 02